Matthew Harrison
Stock Analyst at Morgan Stanley
(0)
# 3429
Out of 5,218 analysts
878
Total ratings
46.45%
Success rate
1.55%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Alector | Downgrades: Underweight | 10 3 | 1.98 | 51.52% | 10 | Nov 26, 2024 | |
Vertex Pharmaceutica... | Maintains: Equal-Weight | 473 476 | 463.5 | 2.7% | 33 | Nov 5, 2024 | |
Regeneron Pharmaceut... | Maintains: Overweight | 1235 1184 | 730.7 | 62.04% | 49 | Nov 1, 2024 | |
Biogen | Downgrades: Equal-Weight | 285 204 | 150.04 | 35.96% | 46 | Oct 31, 2024 | |
IO Biotech | Maintains: Overweight | 4 6 | 0.81 | 640.74% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 2 7 | 2.93 | 134.81% | 9 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 6 | 3.27 | 83.49% | 9 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 85 | 71.53 | 18.83% | 15 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 165 200 | 123.57 | 61.85% | 34 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 8 11 | 16.58 | -33.66% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 38 8 | 3.1 | 158.06% | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 515 510 | 606.64 | -15.93% | 24 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Equal-Weight | 7 | 1.44 | 386.11% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 80 78 | 91.85 | -15.08% | 31 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 112 | 66.03 | 69.62% | 20 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 34 34 | 18.51 | 83.68% | 14 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 32 32 | 20.16 | 58.73% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 42 38 | n/a | n/a | 6 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 14 4 | n/a | n/a | 6 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 321 319 | 179.13 | 78.08% | 27 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 21 19 | 2.9 | 555.17% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 13 14 | 2.75 | 409.09% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 128 123 | 41.83 | 194.05% | 23 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Equal-Weight | 229 229 | n/a | n/a | 23 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 85 | 35.19 | 141.55% | 10 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Underweight | 60 60 | 6.36 | 843.4% | 30 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 21 | n/a | n/a | 7 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 46 | 39.95 | 15.14% | 1 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 61 63 | 22.96 | 174.39% | 11 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 13 | 1.98 | 556.57% | 4 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 0.55 | 81.82% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 10 | 18.59 | -46.21% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 27 8 | 3.97 | 101.51% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 57 44 | 26.76 | 64.42% | 28 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 19 10 | n/a | n/a | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 13 | 1.89 | 587.83% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 4 | 0.68 | 488.24% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 0.52 | 476.92% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 203 216 | 120.2 | 79.7% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 7 5 | 1.87 | 167.38% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 5 | 2.04 | 145.1% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 178 182 | 173.5 | 4.9% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 12 9 | 8.48 | 6.13% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 40 | 28.86 | 38.6% | 6 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 279 282 | 270.45 | 4.27% | 36 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 220 210 | 245.25 | -14.37% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 27 | 0.45 | 5900% | 7 | Sep 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 6 3 | n/a | n/a | 5 | May 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 55 52 | 25.59 | 103.2% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 175 173 | 146.69 | 17.94% | 3 | Apr 6, 2022 |